To relieve confusion about the clinical correlates and prognostic implications of the
Introduction
Although the dexamethasone suppression test (DST) was originally proposed as a specific marker for major depressive disorder (Carroll et al 1981) , studies in schizophrenia have yielded rates of nor, suppression ranging from 0% to 73% (Yeragani 1990 ). Higher rates ol DST nonsuppression in schizophrenia have been attributed to depressive symptoms (Munro et al 1984; Sawyer and Jeffries 1984) , negative symptoms (Coppen et al t983; Shima et al 1986; Tandon et al 1989a) , and the nonparanoid subtype (Banki et al 1984) . tt also has been suggested that DST nonsuppression in schizophrenia may prognosticate a better outcome (Targum 1983; Coryell and Zimmerman 1989) . Most of these findings have not, however, been confirmed in other investigations and the approximately 50 studies of DST in schizophrenia have yielded disc~epant findings.
The present study was conducted in an effort to define the clinical correlates and prognostic implications of the DST response in s~hizophrenia, and study the impact of phase of illness, neuroleptic treatment, and ventricular size. In a preliminary report (Tandon et al 1989a) , we had observed a 35% nonsuppression rate in a sample of 20 medication-free schizophrenic patients, and an association between postdexamethasone cortisol levels and severity of negative symptoms. We now report findings on an expanded sar~ple of 58 patients with regard to frequency of DST nonsuppression in medicationfret. and neuroleptic-treated phases of schizophrenic illness, and relationship of the DST response to symptomatology (positive, negative, and depressive symptoms). In this study, we additionally investigated the relationship c,f the DST response to ventricular size and l-year outcome.
Methods
The original sample consisted of 58 consecutively hospitalized patients who were admitted to the Inpatient Schizophrenia Program at the University of Michigan from [1987] [1988] [1989] . All patients met DSM-III-R (American Psychiatric Association 1987) and Research Diagnostic Criteria (RDC) (Spitzer et al 1978) for schizophrenia. Patients with any medical criteria known to interfere with a valid DST (Carrt, ll et al 1981) were excluded. No patient had received depot neuroleptics for at least 6 months before entering the study. Informed consent was obtained. After patients had been drug-free for a minimum of 2 weeks, clinical ratings, head computed tomegraphy (CT) scan, and a 1 mg DST were performed. Patients were then treated with clinically determined doses of haloperidol, thiothixene, or chlerpromazine [doses of 8-30 mg haloperidol equivalents per day (Baldessarini 1984) ], singly or in combination with 2-6 mg of trihexyphenidyl. After about 4 weeks of such treatment, clinical ~atings and the DST were repeated. Approximately 1 year after the initial drug-free evaluation, outcome was assessed. Outcome could be assessed on 44 of the 58 patients in the original sample.. The remaining patients could not be located. All subjects who had clinical ratings and a valid DST at the drug-free and 4-week posttreatment timepoints, and on whom outcome could be assessed at 1 year were included in the final sample. The final sample of 44 patients consisted of 29 men and 15 women, with a mean (--+SD) age of 29 (---8) years (range 18-46 years). The mean duration of the illness was 7 ( __. 5) years. Of these 44 patients, 15 we~ drug naive (never medi~:ated), ~2 had been noncompliant with prescribed treatment and were drug free for >4 weeks, and 17 were drug free for 2--4 weeks.
Patients were rated by one of the investigators (RT) on the l~-item Brief Psychiatric Rating Scale [BPRS (Overall and Gorham 1962) ], Scale for the Assessment of Negative Symptoms [SANS (Andreasen 1983)] , and the tIamilton Depression Rating Scale [HDRS (H~unilton 1960ji at baseline and about 4 weeks after neuroleptic treatment. Ratings were completed while blind to DST results and head CT findings. Global severity was assessed by the 18-i:em BPRS total score. Positi~;e symptom severity was assessed by the gum of thf following four BPRS items: conceptual disorganization, suspiciousness, hallucinatory ~havier, and unusual thought content. Collectively, these items comprise the BPRS "THOT" factor (Guy 1976; Hedlund and Vieweg 1980) and are most c~mmonly employed to rate positive symptoms. Negative symptoms were assessed by ~e SANS, the sum of global scores being emplo.~ ed Ks the measure of negative symptom severity. The BPRS "ANER" factor, consisting of emotional withdrawal, motor retardation, and blunted affect, was utilized for comparison. Depressive symptom severity was assessed by the 17-item HDRS total score. Change in symptom ratings at 4 weeks was employed as the measure of improvement at 4 weeks.
A l-rag DST (Carroll et al 1981) was performed at drug-free baseline and after about 4 weeks of neuroleptic trea,~nent. The first DST was performed at least 1 week after the patient's hospital admission to permit adaptation (Haskett et al 1989) . Clinical ratings and the corresponding DST were peffo:-cned within 2 day ~, of each other. Blood samples for postdexamethasone cortisol levels were obtained at 4 PM and 11 aM and the t~aaximal cortisol levels were employed for analysis. C~isol was assayed by Murphy's competitive protein-binding method (Murphy 1967) . Maximal postdexamethasone cortisol levels > 5 ~g/dl have been established in our clinical setting to be indicative of nonsuppression (Carroll et al 1981) . Plasma dexamethasone levels were not measured in this study.
A head CT scan was performed on 36 of the 44 patients in the sample and measures of ventricle-brain ratio (VBR) obtained by videoscreen plaJ,Ametry. Two raters (JD and JMW), blind to clinical ratings and DST findings, coilducted these measurements and the mean of two ratings of the maximum VBR on the CT braiz~ slices (LVBR~) on each individual patient was employed for analysis.
Outcome was assessed by the Strauss-Carpenter scale (Strauss and Carpenter 1972; McGlashan 1984) , on which hospitalization, employment, social activity: symptoms, global function, and compliance are all assessed on a 5-point (0--4) scale. A family member/careprovider, and the individual's treating psychiatrist or community mental he~t,h center casemanager were contacted for this assessment by two independent raters (CM and KC) about 1 year after the initial drug-free evaluation. After their independent assessments, a joint conference was held between these raters to arrive at final consensus ratings. The raters were blind to the clinical ratings, DST, and head CT findings.
The relationship between DST findings and other parameters was evaluated by calculating Pearson's product-moment correlations between leg-transformed maximal postdexar, ethasone cortisol levels and clinical ratings, VBR, and outcome measures. Based on DST suppression/nonsuppression at the two timepoints, patients were then divided into the following three groups: patients who were suppressive following dexamethasone at both timepoiets (S-S); patients who were nonsuppressive at drug-free baseline but who eonvelxed .to normal suppression after 4 weeks (NS-S); and those who continued to be nonsuppressors even after 4 weeks of neuroleptic treatment (NS-NS). These groups were compared on clinicai" ratings, VBR, and outcome by analysis of variance (ANOVA).
Results
In the total ~ample, at drug-free baseline, postdexamethasone cortisol levels were significant!y correlated with negative symptom scores measured either by the SANS (r = 0.45; n = 44; p < 0.01) or the BPRS "ANER" factor (r = 0.41;p < 0.0I). F~gure 1 i~Austrates the relationship between baseline postdexamethasone cortisol and the SANS sum of global scores. Baseline postde×amethasone co~isol levels were significantly correlated to four SANS subscale global scores (r = 0.39--9.49; p < 0.05 for affective blunting, avolition--apathy, anhedonia-asociality, and attentional impairment) and showed a trend toward significant relationship with the alogia subscale global score (r = 0.31; . Similarly, baseline postdexamethasone co,tisol levels were unrelated to age, sex, VBR, improvement of symptoms at 4 weeks, or any index of outcome at 1 year. (Similar imdings were obtained when the larger sample of 58 patients, including 14 on whom outcome data not available, was considered.) ,'ostdexamethasone cortisol levels were significantly correlated to change in SANS sum of global scores during neuroleptic treatment (r = 0.38; p < 0.05). At the 4-wee~ posttreatment timepoint, postdexamethasone cordsol levels were unrelated to negative symptoms (r = 0.13; NS), positive symptoms (r = 0.15; NS), depressive symptoms (r = 0.13; NS), or global severity (r = 0.23; NS). There also was no asseciation with age, sex, VBR, or outcome at 1 year. Drug-free and 4-week posttreatment postdexamethasone cortisol levels were significantly correlated (r = 0.42; p < 0.01).
The BPRS total (mean _+ SD) o~t the entire sample at medication-free baseline was 49 ( --7.5). The mezal severity of positive symptoms (measured by the BPRS "THOT" subscale) and negative symptoms (measured by the SANS sum of global scores) were t5.7 (_+ 3.0) and 13.2 (_ 3.9) respectively. Both posltivc and negative symptoms improved with neuroleptic treatment; the mean positive and negative symptom severity at 4-weeks posttreatment were 9.5 ( -+ 3.1) and 8.8 ( -+ 3.9) respectively. The mean maximal postdexamethasone cortisol was 5.5 (+-_ 5.0) at drug-free baseline and 2.6 (--2.6) at 4-weeks posttreatment. Head CT scans from 36 patients resuRed in a mean -+ SD LVBR~.ax of 0.08 ( +-0.03). 1991;29:953 964 S~'1enteen of the a4 patients ¢39%) were DST nor, suppressors at baseline, including five of 15 previously never-medicated patients, in the larger sample of 58 patients, 22 were nonsuppressors, yielding a similar nonsuppression rate of 38% at drug-free baseline. Although all patients were drug-free t0r at least 2 weeks before the initial DST, Kxaus et al (1988) have suggested that w:xhdrawal of neuroleptics-anticholinergics may produce DST nonsuppression lasting up to 21 days. Analysis of the data to examine for this possibility revealed that in our final sample, 15 patients were drag naive, 12 patients were drug free >4 weeks, and 17 patients were drug free for 2-4 weeks. Five of the t5 drug-naive patients (33%), five of the 12 patients drag free >4 weeks (42%), and seven of the i7 patients drug free for 2-4 weeks (41%) were DST nonsuppressors. Thus, psychotropic withdrawal effects apparently did not account for the DST f~ndings obse~-cd in our study.
Of the 17 baseline DST nonsuppressors 12 became normally suppressive (NS-S) at 4-weeks posttreatment. Gi the 27 patients who were DST suppressors at drug-free baseline, 26 remained suppressive (S-S), while one became a DST nonsuppressor at 4-weeks posttreatment. This patient was classified with the five pers stent DST nonsuppressors in the NS-NS group. The three groups are compared on symptom ratings, VBR, and outcome in Table 1 . The three groups did not differ in age or sex ¢ stsSbufion. While there was no statistical difference in maximal VBR between the three groups, persistent DST nonsuppressors tended to have larger VBR (F = 1.8; df = 2,33; F < 0~19).
At drug-free baseline, ,,he three groups did not differ with regard to severity of positive symptoms, depression, or global severity. Both persistent DST non~uppressors and normalizing DST nonsuppressors had significantly higher negative symptom scores than the persistent DST suppressor group. By definition, both the DST nonsuppressor groups had significantly higher postdexamethasone cortisol levels than the DST suppressor group.
After 4 weeks of clinically determined neuroleptic treatment, the three groups did not differ with regard to severity of positive symptoms, depression, or global severity. The persistent DST nonsupyressor group had significantly higher negative symptom ratings than the persistent DST suppressor and normalizing DST nonsuppressor (suppressor at this timepoint) groups. Again by definition, the persistent DST nonsuppressor group had higher mem~ postdexamethasone cortisol than the other two groups.
After 4 weeks of neuroleptic treatment, the normalizing DST nozsuppressor group showed significantly greater improvement in both negative symptoms and global severity than the other two groups. There were no differences ~tween the three groups with regard to degree of improvement of positive or depressive symptoms.
There were significant differences between the three groups with regard to l-year outcome. The persistent DST nonsuppressor group had significantly worse total outcome than thc other two groups. While the normalizing DST nonstlppr~ "~r group had somewhat. b:,tter o~tcome than the persistent DST suppressor group, this di~,~,ence was not statiso t~'ally significant. The three groups did no~ differ with regard to treatment compliaace.
Discussion
Thirty-nine percent (17 of 44) of schizop~-enic patients were DST nonsuppressors at medication-free baseline. Four weeks after neuroleptic treatment, 14% (6 of 441 of these patients remained DST nonsuppressors. The rate of DST nonsuppression ob.,;erved in our sample is intermediate between the 0% to 73% reported in the literature and is comparable to data reported in most recent studies (Table 2 ). All studies of the t -rag DST in schizophrenia (not schizoaffective disorder) with a sample size >10, wfuch employed a post- One-year outcome Hospitalizatiofl 3.6 4. 0.~' 3.9 -+ 0. 2.4 4-1.1 2.7 -+ l.l 1.6 ± 0.9 NS Total 12.1 4-2.0 13.3 4-2.1 9.2 ± 1.7 F = 3.5; p <0.05 Compliance 3.2 ± 1.1 3.1 ± 1.4 3.5 4-0.8 NS dexamet.hasone cortiso! value of 5 ;~g/dl as the cutoff for nonsuppression are enumerated in this table° A summary meta-analysis o, ~ these studies reveal.~; a DST non~uppre~,~sion rate of 36% in the drag-free stare (39% in our sample) and 20% ir~ the medicated state (14% in our sample). These data suggest that phase of fllnes:; and medication status influence rates of DST nonst,-pression in schizophrenia and m partially account for the discrepant findings in the ttterature. Rates of DST nonsuppression are higher in drugfree schizophrenic patients in the acute phase of the illness. The significant reduction in rates of DST nonouppression that we observed after 3-4 weeks of neuroleptic treatment is consistent with this suggestion and with findings of other studies in which the DST was Fefforme~ before and after neuroleptic treatment (Herz et al t985; Holsboer-Trachsler et al 1987; Moiler et al 1986; Tandon et al 1989a; Wik et al 1986) .
The association between postdexamethasone cortisol levels and severity of neg,,dve symptoms observed in our study is in agreement with eight of the 12 other studies that evaluated this association (refer to Table 2 ). We observed an association between postdexamethasone cortisol and negative symptoms in the drug-free state, but not after 3-4 weeks of neuroleptic treatment. These findings are similar to those of the Stanford group, who observed no relationship between postdexamethasone cortisol and negative symptoms in chronic, medicated schizophrenic patients (Whiteford et al 1988) , but observed such a relationship in acute, unmedicated patients (Faustman et a11990) . These data, in addition to the association between postdexamethasone cortisol levels and change in negative symptoms observed in ou~" study, may indicate that in the acute phase of the illness, postdexamethasone cortisol levels are related to nonenduring negative symptoms (Carpenter et al 1988; Tandon et al 1990; Tandon and Greden 1990a) . Our failure to find any association between postdexamethasone cortisol and depressive symptoms is consistent with the findings of 13 of the 17 studies tbat assessed this association (refer to Table 2 ). Despite the phenomenological overlap between negative and depressive symptoms and consequent difficulty in differentiating between them (Sommers 1985; Addington and Addington 1990) , recent studies indicate that these phenomena can be distinctly measured in schizophrenia (Barnes et al 1989; Newcomer et al 1990; Liberzon et al 1990) . Our finding of an association between postdexamethasone cortisol levels and negative symptoms, but not with depressive symptoms, would support this contention. We found no other relationship between postdexamethasone co_rtisol and global severi~', a finding consistent with other studies that evaluated this association (Dewan et al 1982; Shima et al 1986; Tandon et al 1989a) .
The observed relationship between DST findings and outcome was complex. Baseline postdexamethasone cortisol itself was unrelated to outcome at 4 weeks or 1 year. The pattern of baselipe DST nonsuppression converting to normal suppression after 4 weeks of neuroleptic treatment was associated with significantly greater improven,ent in both negative symptoms and global severity at 4 weeks; this finding is consistent with our previous finding (Tandon et al 1989a) and those of Holsboer-Trachsler et al (1987) . Conversely, persistent DST nonsuppressicn was associated with greater negative symptom severity at 4 weeks and poor outcome at 1 year. These findings parallel those in major depression, where normalizing baseline DST nonsuppression is associated with greater clinical improvement (Greden et al 1983; Brown and Quails 1981; Baldessai-Jni and Arana 1985) , and persistent DST nonsuppression is associated with poor outcome (Greden et al 1983; Baldessarini and Arana 1985) .
Our findings appear to be at variance with those of CoD, ell and Zimmerman (1989); they observed an association between baseline DST nonsuppression and good 1-year outcome in functional psychosis, including schizophrenia. The following methodological differences may have contributed to this discrepancy: (1) in their study, the baseline DST was not always performed under drug-free conditions; (2) the association between postdexamethasone cortiso! levels and good l-year outcome noted in their study was somewhat equivocal with regard to the schizophrenic group (Tandon et al 1989b) , and (3) because they were studying the association of baseline drug-free DST, their group of initial DST nonsuppressors included both normalizing nonsuppressors (associated with better 4-week outcome in our study) and persistent DS'I nonsuppressors (associated with worse 1-year outcome in our study).
Pathophysiological mechanisms that may underly these phenomena are not known. Normalizing DST nonsuppression may be related to stress, cholinergic hyperactivity (Carroll et al 1980; Tandon arid Greden 1989 , 1990b , or some other mechanism associated with better resolution of the index psychotic episode. The association between negative symptoms and postdexamethasone cortisol at drug-free baseline, but not at 4-weeks posttreatment is consistent with this suggestion Greden 1989, 1990b) . The greater improvement in negative symptoms with 3-4 weeks of neumlepfic treatment in the normalizing DST nonsuppressor group and other data indicating that postdexamethasone cortisol levels are related to nonendudng negative symptoms in the acute phase would also support this hypothesis. On the other hand, persistent DST nonsuppression may be related to some other mechanism (such as enlarged ventricles, Rothschild et al 1989) that may be associated with poor outcome (Coppen et al ! 983) . In the present study, the persistent DST nonsuppressor group tended to have greater VBR (although this difference was not statistically significant, perhaps related 1o the small number of patients in this group, n = 6) and poor 1-year outcome. However, these explanations remain speculative.
In summary, a significant proportion of schizophrenic patients exhibit abnormal feedback regulation in the hypothalamic-pituitary-adrenal axis, as reflected in DST nonsuppression. A greater proportion of schizophrenic patients exhibit DST nonsuppression in the medication-free phase than in the neuroleptic-treated phase. There is a significant association between postdexamethasone cortisol and severity of negative symptoms, particularly in the drug-free phase. There appears to be no association between DST findings in schizophrenia and severity of depressive symptoms. Normalizing DST nonsuppression appears to be associated with greater clinical improvement with neuroleptic treatment. Persistent DST nonsuppression appears to be associated with worse outcome. While dist;,nc~ mechanisms may underlie these phenomena, the pathophysiological bases of DST nonsuppressk, n in schizophrenia remain unclear. Future studies should take medication status and phase of illness into consideration, as these appear to be important confounding variables.
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